Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody

American Journal of Transplantation

Volumn 15, Issue 11, 2015, Pages 2921-2930

  Wiebe, C ^a   Gibson, I W ^a   Blydt Hansen, T D ^b   Pochinco, D ^c   Birk, P E ^a   Ho, J ^a   Karpinski, M ^a   Goldberg, A ^a   Storsley, L ^a   Rush, D N ^a   Nickerson, P W ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; MYCOPHENOLATE MOFETIL; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ARTICLE; B LYMPHOCYTE; CLINICAL EVALUATION; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DISEASE COURSE; FIBROSING ALVEOLITIS; FLUORESCENCE IMAGING; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TIME TO TREATMENT; TUBULAR ATROPHY; ACUTE DISEASE; ADVERSE EFFECTS; AGE; ALLOGRAFT; CHILD; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; GRAFT REJECTION; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TIME FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGE FACTORS; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; DELAYED GRAFT FUNCTION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84945465561     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13347     Document Type: Article

References (43)

1. Archdeacon P, Chan M, Neuland C, et al., Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
2. Wiebe C, Gibson IW, Blydt-Hansen TD, et al., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
3. Everly MJ, Rebellato LM, Haisch CE, et al., Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417.
4. Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
5. Rosner A,. Fundamentals of biostatistics. 6th ed. Belmont, CA: Thomson-Brooks/Cole; 2006e.
6. Wiebe C, Pochinco D, Blydt-Hansen TD, et al., Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114-3122.
7. Kasiske BL, Gaston RS, Gourishankar S, et al., Long-Term deterioration of kidney allograft function. Am J Transplant 2005; 5: 1405-1414.
8. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW,. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-163.
9. Thompson A, Lawrence J, Stockbridge N,. GFR decline as an end point in trials of CKD: A viewpoint from the FDA. Am J Kidney Dis 2014; 64: 836-837.
10. Coresh J, Turin TC, Matsushita K, et al., Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311: 2518-2531.
11. Nevins TE, Robiner WN, Thomas W,. Predictive patterns of early medication adherence in renal transplantation. Transplantation 2014; 98: 878-884.
12. Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ,. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014; 85: 1404-1411.
13. Hansen R, Seifeldin R, Noe L,. Medication adherence in chronic disease: Issues in posttransplant immunosuppression. Transplant Proc 2007; 39: 1287-1300.
14. De Geest S, Borgermans L, Gemoets H, et al., Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340-347.
15. Servick K,. Nonadherence: A bitter pill for drug trials. Science 2014; 346: 288-289.
16. Halloran PF, Aprile MA, Farewell V, et al., Early function as the principal correlate of graft survival. Transplantation 1988; 46: 223-228.
17. Hariharan S, Mcbride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP,. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
18. Quiroga I, McShane P, Koo DD, et al., Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689-1696.
19. Siedlecki A, Irish W, Brennan DC,. Delayed graft function in the kidney transplant. Am J Transplant 2011; 11: 2279-2296.
20. Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV,. Ischemia/reperfusion injury in human kidney transplantation: An immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998; 153: 557-566.
21. Oberbarnscheidt MH, Zeng Q, Li Q, et al., Non-self recognition by monocytes initiates allograft rejection. J Clin Invest 2014; 124: 3579-3589.
22. Tait BD, Süsal C, Gebel HM, et al., Consensus guidelines on the testing and clinical management issues associated with HLA and non-hla antibodies in transplantation. Transplantation 2013; 95: 19-47.
23. Reed EF, Rao P, Zhang Z, et al., Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859-1870.
24. Dieplinger G, Everly MJ, Rebellato LM, et al., Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction. Transplantation 2014; 98: 1097-1104.
25. Haas M, Sis B, Racusen LC, et al., Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
26. Wavamunno MD, O'Connell PJ, Vitalone M, et al., Transplant glomerulopathy: Ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7: 2757-2768.
27. Halloran PF, Chang J, Famulski K, et al., Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol 2014; Epub ahead of print.
28. de Kort H, Willicombe M, Brookes P, et al., Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13: 485-492.
29. Pearl JP, Parris J, Hale DA, et al., Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated t-cell depletion. Am J Transplant 2005; 5: 465-474.
30. Bloom D, Chang Z, Pauly K, et al., BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9: 1835-1845.
31. Todeschini M, Cortinovis M, Perico N, et al., In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol 2013; 191: 2818-2828.
32. Knechtle SJ, Pirsch JD, Fechner H, et al., Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722-730.
33. Sellarés J, de Freitas DG, Mengel M, et al., Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
34. Stegall MD, Gaston RS, Cosio FG, Matas A,. Through a glass darkly: Seeking clarity in preventing late kidney transplant failure. J Am Soc Nephrol 2015; 26: 20-29.
35. Hidalgo LG, Campbell PM, Sis B, et al., De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
36. Sis B, Einecke G, Chang J, et al., Cluster analysis of lesions in nonselected kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 2010; 10: 421-430.
37. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD,. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
38. Lesage J, Noël R, Lapointe I, et al., Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation 2015; 99: 69-76.
39. Einecke G, Sis B, Reeve J, et al., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
40. Halloran PF, De Freitas DG, Einecke G, et al., Personal viewpoint: An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
41. Moreso F, Carrera M, Goma M, et al., Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93: 41-46.
42. El Ters M, Grande JP, Keddis MT, et al., Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13: 2334-2341.
43. Poggio ED, Wang X, Weinstein DM, et al., Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100-108.